X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1117) 1117
humans (1107) 1107
female (937) 937
oncology (895) 895
topotecan (874) 874
middle aged (708) 708
aged (668) 668
adult (641) 641
chemotherapy (555) 555
male (539) 539
topotecan - administration & dosage (503) 503
topotecan - adverse effects (450) 450
antineoplastic combined chemotherapy protocols - therapeutic use (409) 409
cancer (387) 387
treatment outcome (341) 341
ovarian neoplasms - drug therapy (326) 326
antineoplastic agents - adverse effects (324) 324
antineoplastic combined chemotherapy protocols - adverse effects (321) 321
cisplatin (303) 303
drug administration schedule (283) 283
antineoplastic agents - therapeutic use (271) 271
paclitaxel (255) 255
topotecan - therapeutic use (237) 237
lung neoplasms - drug therapy (234) 234
neoplasm recurrence, local - drug therapy (227) 227
aged, 80 and over (220) 220
ovarian cancer (210) 210
carcinoma (207) 207
camptothecin - analogs & derivatives (206) 206
antineoplastic agents - administration & dosage (205) 205
trial (199) 199
infusions, intravenous (190) 190
pharmacology & pharmacy (184) 184
dose-response relationship, drug (168) 168
care and treatment (162) 162
carboplatin (160) 160
camptothecin - adverse effects (158) 158
obstetrics & gynecology (158) 158
disease-free survival (156) 156
etoposide (149) 149
research (148) 148
neoplasms - drug therapy (145) 145
medicine & public health (136) 136
antineoplastic combined chemotherapy protocols - administration & dosage (133) 133
paclitaxel - administration & dosage (130) 130
camptothecin - administration & dosage (129) 129
phase-ii (126) 126
survival analysis (125) 125
drug resistance, neoplasm (124) 124
therapy (122) 122
cisplatin - administration & dosage (120) 120
survival rate (119) 119
carboplatin - administration & dosage (118) 118
hematology, oncology and palliative medicine (118) 118
camptothecin (117) 117
solid tumors (116) 116
cyclophosphamide (115) 115
adolescent (113) 113
gynecologic-oncology-group (110) 110
clinical trials (109) 109
irinotecan (108) 108
lung neoplasms - pathology (108) 108
topotecan - pharmacokinetics (108) 108
child, preschool (107) 107
neoplasm staging (104) 104
neutropenia - chemically induced (104) 104
ovarian neoplasms - pathology (104) 104
antineoplastic agents - pharmacokinetics (102) 102
child (102) 102
toxicity (100) 100
antineoplastic agents (98) 98
hematology (98) 98
carcinoma, small cell - drug therapy (97) 97
drug therapy (97) 97
etoposide - administration & dosage (96) 96
camptothecin - therapeutic use (95) 95
combination (95) 95
pharmacokinetics (95) 95
retrospective studies (95) 95
gemcitabine (94) 94
cell lung-cancer (91) 91
antimitotic agents (88) 88
oncology, experimental (85) 85
pharmacology/toxicology (85) 85
small cell lung carcinoma - drug therapy (85) 85
doxorubicin (82) 82
lung cancer (81) 81
maximum tolerated dose (81) 81
recurrence (81) 81
topoisomerase-i (81) 81
survival (79) 79
analysis (78) 78
doxorubicin - administration & dosage (78) 78
paclitaxel - adverse effects (78) 78
recurrent (78) 78
tumors (78) 78
topoisomerase i inhibitors (76) 76
animals (74) 74
pegylated liposomal doxorubicin (74) 74
relapse (74) 74
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1186) 1186
Chinese (10) 10
Italian (7) 7
French (6) 6
Japanese (5) 5
German (2) 2
Korean (2) 2
Polish (2) 2
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1309 - 1316
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 19, pp. 3107 - 3114
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2014, Volume 370, Issue 8, pp. 734 - 743
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2016, Volume 27, Issue 8, pp. 1579 - 1585
The combination of the campothecan-containing nanoparticle-drug conjugate, CRLX101 and bevacizumab is well tolerated, safe, and active in a heavily pretreated... 
Hypoxia-inducible factor | Angiogenesis | CRLX101 | Recommended phase II dose | Nanoparticle-drug conjugate | Renal cell carcinoma | renal cell carcinoma | nanoparticle-drug conjugate | EVEROLIMUS | ONCOLOGY | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA | angiogenesis | recommended phase II dose | TOPOTECAN | hypoxia-inducible factor | CANCER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cyclodextrins - adverse effects | Nanoparticles - chemistry | Antineoplastic Combined Chemotherapy Protocols - chemistry | Bevacizumab - adverse effects | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Adult | Camptothecin - administration & dosage | Female | Carcinoma, Renal Cell - drug therapy | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Carcinoma, Renal Cell - pathology | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Cyclodextrins - administration & dosage | Aged | Nanoparticles - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Index Medicus | nanoparticle–drug conjugate | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2017, Volume 23, Issue 19, pp. 5711 - 5719
Purpose: We evaluated a Trop-2-targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients. Experimental Design: Sacituzumab... 
PHASE-III TRIAL | MULTICENTER | SOLID TUMORS | ONCOLOGY | CYCLOPHOSPHAMIDE | TOPOTECAN | VINCRISTINE | OPEN-LABEL | 1ST-IN-HUMAN | COMBINATION | CHEMOTHERAPY | Humans | Middle Aged | Cell Adhesion Molecules - antagonists & inhibitors | Male | Cell Adhesion Molecules - immunology | Molecular Targeted Therapy | Immunoconjugates - administration & dosage | Small Cell Lung Carcinoma - drug therapy | Drug-Related Side Effects and Adverse Reactions - pathology | DNA Topoisomerases, Type I - immunology | Antibodies, Monoclonal, Humanized - administration & dosage | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Camptothecin - immunology | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antigens, Neoplasm - immunology | DNA Topoisomerases, Type I - genetics | Kaplan-Meier Estimate | Topoisomerase I Inhibitors - administration & dosage | Immunoconjugates - chemistry | Disease-Free Survival | Small Cell Lung Carcinoma - pathology | Topoisomerase I Inhibitors - adverse effects | Aged | Small Cell Lung Carcinoma - immunology | Drug-Related Side Effects and Adverse Reactions - classification | Slopes | Statistical analysis | Anemia | Lung cancer | Antibodies | Diarrhea | Fatigue | Topotecan | Shrinkage | Patients | Survival | Metastases | Chemotherapy | Motivation | Experimental design | Quality | Safety engineering | Neutropenia | Cancer | Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 09/2018, Volume 19, Issue 9, pp. 1247 - 1258
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 31, pp. 3841 - 3847
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2012, Volume 30, Issue 4, pp. 1493 - 1500
Background The aim of this phase I study was to determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of orally administered... 
Medicine & Public Health | Targeted agents | PARP inhibitors | Oncology | Topotecan | Olaparib | Maximum tolerated dose | Pharmacology/Toxicology | DNA repair | SENSITIVITY | INDUCTION | CANCER | MAMMARY-TUMORS | ONCOLOGY | RESISTANCE | PHARMACOLOGY & PHARMACY | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Demography | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Enzyme Inhibitors - adverse effects | Phthalazines - administration & dosage | Topotecan - adverse effects | Treatment Outcome | Piperazines - therapeutic use | Neoplasms - diagnostic imaging | Topotecan - therapeutic use | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Neoplasms - drug therapy | Maximum Tolerated Dose | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - pharmacokinetics | Topotecan - administration & dosage | Aged | Phthalazines - adverse effects | Cohort Studies | Studies | Clinical trials | Inhibitor drugs | Drug therapy | Patients | Tumors | Index Medicus
Journal Article
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 12/2016, Volume 27, Issue 12, pp. 2236 - 2241
Journal Article
Journal Article